ACTA2 and central nervous system cancer: Comparing ACTA2 expression in initial and recurrent samples from the same glioma patients, we noted that ACTA2/RPL37 increased nearly twofold in recurrent cases (median value: 2.05, range: 0.12–17.39) compared to initial cases (median value: 0.90, range: 0.04–4.10).